


VOLUME 99 OCTOBER 2018

NUMBER 4 SUPPLEMENT

## SIXTY-SEVENTH **ANNUAL MEETING** Sheraton New Orleans and New Orleans Marriott | New Orleans, LA USA

October 28 - November 1, 2018

# "There will be epidemics..."



Supplement to The American Journal of Tropical Medicine and Hygiene

## **Sponsored Symposium**

#### From R&D to Access for Sleeping Sickness Elimination: Innovative Public-Private Partnerships for New Tools

Sponsored by Sanofi and Drugs for Neglected Diseases initiative (DNDi)

Sheraton - Waterbury (2nd Floor) Monday, October 29, 7:15 p.m. - 9:15 p.m.

The first all-oral treatment for *Trypanosoma brucei gambiense* human African trypanosomiasis (g-HAT), co-developed through an innovative public-private partnership between Sanofi and the Drugs for Neglected Diseases *initiative* (DND*i*) has proven to be effective and safe, according to results of clinical trials led by DND*i* and numerous partners in DR Congo and Central African Republic, and published in *The Lancet* in October 2017. This new drug joins new diagnostics to round out the elimination toolbox for this fatal disease that is now at a historical low in terms of global disease burden.

#### CO-CHAIR

Victor Kande Betu Kumeso

NTD Director, Ministry of Health, Kinshasa, Democratic Republic of the Congo

Luc Kuykens Senior Vice-President Global Health Programs, Sanofi, Gentilly, France

#### SESSION INTRODUCTION

Victor Kande Betu Kumeso NTD Director, Ministry of Health, Kinshasa, Democratic Republic of the Congo

#### **DISCUSSION FACILITATION**

Luc Kuykens Senior Vice President Global Health Programs, Sanofi, Gentilly, France

#### AN ALTERNATIVE MODEL FOR DRUG DEVELOPMENT: THE STORY OF FEXINIDAZOLE

Nathalie Strub-Wourgaft Clinical Director, Drugs for Neglected Diseases initiative, Geneva, Switzerland

#### WORKING IN PARTNERSHIP FOR SLEEPING SICKNESS ELIMINATION: USING NEW TECHNOLOGIES

Erick Mwamba Miaka Director, National HAT Programme, Kinshasa, Democratic Republic of the Congo

### FINDING EVERY LAST CASE: THE ROLE OF DIAGNOSTICS IN HAT ELIMINATION

Veerle Lejon Research Director, Institut de Recherche pour le Développement, Montpellier, France

### ROLL-OUT OF ALL-ORAL TREATMENT: INTRODUCING A DONATION PROGRAM FOR SLEEPING SICKNESS

Luc Kuykens Senior Vice-President Global Health Programs, Sanofi, Gentilly, France

#### STRIVING TOWARDS HAT ELIMINATION IN SOUTH SUDAN: AN OPERATIONAL PERSPECTIVE

Laurence Flévaud Operational Centre Barcelona-Athens, Médecins Sans Frontières

#### MONITORING HAT ELIMINATION: PLANS FOR VALIDATION

Gerardo Priotto Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland